- Investors & Media
- Investors & Media
- Contact Us
NESS ZIONA, Israel—December 09, 2013–
Kamada Ltd. (Nasdaq:KMDA)(TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the appointment of Amir London to the newly-created position of Senior Vice President, Business Development. Mr. London will serve as a member of Kamada's executive leadership team and will lead Kamada's commercial strategy and business development efforts to advance the market opportunities for the company's protein therapeutics platform through a variety of initiatives including collaborations and partnerships, as well as enhancing Kamada's sales infrastructure.
Mr. London brings over 20 years of senior management and international business development experience, most recently as Chief Operating Officer of Fidelis Diagnostics, a US-based provider of innovative in-office medical diagnostic services.
"We are delighted to have Amir join our team. I am confident the depth and breadth of his experience will significantly enhance Kamada's opportunities to advance the commercial prospects for a variety of our very promising pipeline programs, certain of which are in late-stage clinical development," said David Tsur, Chief Executive Officer of Kamada.
"This is an exciting time to be joining the Kamada team. With a number of promising products and product candidates in high-value therapeutic areas, the Company is in a strong position to leverage the potential of its plasma-derived protein therapeutics platform," noted Mr. London. "I look forward to working with this dynamic leadership team to expand our clinical and commercial opportunities in order to enhance our shareholder value."
Prior to Fidelis Diagnostics, Mr. London was the CEO of Promedico, a leading Israeli-based $350 million healthcare distribution company. Previous to that, he was the General Manager of Cure Medical, a contract manufacturing service provider for clinical studies, as well as home-care solutions. During the prior 10 years, Mr. London was a Partner with Tefen, an international, publicly-traded operations management consulting firm, where he was responsible for the firm's global biopharmaceutical practice.
Mr. London holds a B.Sc. in Industrial and Management Engineering from the Technion in Haifa, Israel.
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company's flagship product is Glassia(R), the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International. In addition to Glassia, Kamada has a product line of nine other pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that is nearing completion of pivotal Phase II/III clinical trials in Europe and will be entering Phase II clinical trials in the U.S. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, clinical trials, the EMA and U.S. FDA authorizations and timing of clinical trials. Forward-looking statements are based on Kamada's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Anne Marie Fields